Company: ARWR
Filing Date: 2025-01-29
Form Type: ARS
Source: 0001628280-25-002866
Chunk: 111

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: ARS
Chunk 111
---
. It is also responsible for evaluating the materiality of information for SEC filings and, as required or as otherwise appropriate, coordinates with the Company’s Materiality Committee to support timely disclosure of relevant information. ITEM 2. PROPERTIES The following table summarizes the Company’s leased facilities as of November 20, 2024. Approximate Square Footage Primary Use Lease Expiration Remaining Lease Term (year) Pasadena, California 49,000 Corporate Headquarters April 2027 2.5 Madison, Wisconsin 107,000 Research Facility September 2031 6.9 San Diego, California 144,000 Research and Office Facility April 2038 13.5 59

The Company owns land in the Verona Technology Park in Verona, Wisconsin, which has been developed into an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility which will support the Company’s manufacturing process development and analytical activities. During fiscal year 2024, the Company completed the build out of one of its laboratory and office facilities and plans to finalize the manufacturing facility by the end of the first quarter of fiscal year 2025. ITEM 3. LEGAL PROCEEDINGS Legal Proceedings are set forth in the Company’s financial statement schedules in Part IV, Item 15 of this Annual Report on Form 10-K and are incorporated herein by reference. See Note 7 — Commitments and Contingencies of Notes to Consolidated Financial Statements of Part IV, “Item 15. Exhibits and Financial Statement Schedules.” ITEM 4. MINE SAFETY DISCLOSURES Not applicable. 60

PART II ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES Market Information Shares of the Company’s common stock are traded on The Nasdaq Global Select Market under the symbol “ARWR.” There were 89 holders of record of the Company’s common stock as of November 20, 2024. Dividends The Company has never paid dividends on its common stock and does not anticipate that it will do so in the foreseeable future. Recent Sales of Unregistered Securities To the extent required by Form 10-K, the disclosures set forth in Part II, Item 9B of this Annual Report on Form 10- K under the headings “Stock Purchase Agreement” and “Securities Purchase Agreement” are incorporated herein by reference. Repurchases of Equity Securities None